Extended spectrum β-lactamase (ESBLs), produced by Gram negative organisms, are enzymes capable of hydrolyzing extended spectrum cephalosporins, penicillins and monobactam but inactive against cephamycin and imipenem. Detection of some ESBL strains are missed by Double disc synergy test but detected by three dimensional test. So this study was carried out to see the rate of ESBL producer by three dimensional test and double disc synergy test among Gram negative bacteria. Total 110 Gram negative isolates were studied, among them 30 were wound swab isolates and 80 were laboratory isolates, of which 88(80%) were ESBL producer. Three dimensional tests detected ESBL in 88 (80%) strain whereas 66.36% strains detected by double disc synergy test, so 15 (13.63%) isolates were missed by Double disc synergy test. In this study among the 30 wound swab isolates Three dimensional test detected 26 (86.67%) whereas 14 (46.67) were detected by double disc synergy test and similarly among the 80 laboratory isolates, three dimensional test detected 62 (77.5%) and double disc synergy test detected 59 (73.75%). So, the three dimensional test has been found to be better than Double disc synergy test in the detection of ESBLs. ESBL producing organisms are resistance to most of the antibiotics but 100% sensitive to Imipenem.
Introduction
The emergence and spread of drug resistance in enterobacteriaceae is a growing concern in human medicine. Resistant bacterial strains have emerged and have spread throughout the world because of the remarkable genetic plasticity of the micro-organism, heavy selective pressure of antibiotic use and the mobility of the world population. The spread of extended spectrum β-lactamases (ESBLs) producing Gram negative bacteria has become a major concern among multidrug resistant organisms. 1 ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins (e.g., ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g., aztreonam) but do not affect cephamycins (e.g., cefoxitin and cefotetan) or carbapenems (e.g., meropenem or imipenem). by plasmids and are the products of point mutations at the active site of TEM, SHV and OXA enzymes. 4 Most of the clinical diagnostic laboratories depend on traditional susceptibility tests to screen for ESBL production among Gram Negative organisms which unfortunately lacks both sensitivity and specificity to detect ESBLs. 5 Another method of ESBL detection is doubledisk synergy test (DDST). The major advantage of this method is that it is technically simple. However the sensitivity of DDST may be reduced when ESBL activity is very low, leading to wide zones of inhibition around the cephalosporin and aztreonam disks, the inability of clavulanate to inhibit all ESBLs, the inability of the test to detect ESBLs in strains that also produces chromosomal cephalosporinases, and the loss of clavulanate disc potency during storage. 6, 7 Another disadvantage of this test is that the synergy between the amoxicillinclavulanate disc and the indicator cephalosporin may be overlooked if the inoculum is too heavy or if the discs are too far from each other. 8 All these things cause diagnosis failure and mis-use of antibiotics. Three dimentional test (TDT) is another method to detect ESBL production in gram negative bacteria. TDT gives phenotypic evidence of ESBL-induced inactivation of extendedspectrum cephalosporin or aztreonam without relying on the demonstration of inactivation of the β-lactamases by a β-lactamase inhibitor. 7 Two type of Three dimensional test, direct or indirect were proposed by Thomson and Sanders. In some ESBL detection cases by direct test, the zones of inhibition are small or absent which are difficult to interpret as ESBL but these cases are detected by indirect test. If the indirect test is used, the three-dimensional test is reported to be more sensitive than the double-disk diffusion test. 9 So the present study was designed to detect the ESBL production in gram negative bacteria by three-dimensional test and to compare it with the double disc synergy test and analyze antimicrobial susceptibility of the bacterial isolates. 7 Muller Hinton Agar (MHA) plates were seeded with the inoculum of a standard sensitive strain (Escherichia.coli ATCC 25922) adjusted to MacFarland 0.5 standard. 4 wells, each 4 mm in diameter, were punched on inoculated agar plates. 30 µl suspension of test organism suspended in sterile distilled water with turbidity preadjusted to 5.0 McFarland standards was poured into each well. A disc of ceftazidime, ceftriaxone, cefotaxime and aztreonam each were placed about 2 mm away towards the center of the plate from the wells. The plate was then incubated at 37 0 C for 16-18 hours. Heart shaped distortion of zone of inhibition around the antibiotic disc indicates ESBL production. 10 Mueller Hinton agar plates were seeded with standardized inoculum of the test organism (corresponding to 0.5 McFarland tube). Augmentin (20 µg amoxicillin and 10 µg clavulanic acid) disc was placed in the center of the inoculated plate. Three 3rd generation cephalosporin (ceftazidime 30μg, ceftriaxone 30μg, cefotaxime 30μg) and one monobactam (aztreonam 30μg) discs were placed at 20 mm distance from augmentin disc. The plate was incubated overnight at 37 0 C. Extension of the edge of the inhibition zone of ceftazidime, ceftriaxone, cefotaxime and aztreonam disc on the side exposed to the augmentin disc is positive for ESBL production. This extension of edge of inhibition is due to synergy of disc of Augmentin with the four discs used. 11 All the isolates were tested for antimicrobial sensitivity using disc diffusion technique by "Kirby-Bauer method" 11 
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. Susceptibility and resistance was determined based on the interpretative criteria recommended by the Clinical and Laboratory Standards Institute.12 E. coli ATCC 25922 was used as the quality control strain.
Result
A total of 110 Gram negative isolates were studied, of which 30 isolates were from wound swab and 80 from laboratory isolates. Among the 110 isolates, 88 (80%) were ESBL producers. Out of 30 Gram negative organisms isolated from wound swabs from Burn Unit of Dhaka Medical Collage Hospital (DMCH), 26 (83.33%) were ESBL producer and among the 80 BSMMU laboratory isolates, 62 (77.5%) were ESBL producers. The difference in ESBL production between wound swab isolates and laboratory isolates were not significant. 
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Discussion
Extended-spectrum beta-lactamases (ESBLs) constitute a growing class of plasmid-mediated ß-lactamases which confer resistance to broad spectrum beta-lactam antibiotics.
They are commonly expressed by Enterobacteriaceae but the species of organisms producing these enzymes are increasing and this is a cause for great concern.
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Pulse Volume 6 (1 & 2) 2013 Table 2 : Detection of ESBL production by three dimensional test (TDT) and double disc synergy test (DDS) among the all strains studied (n=110). The prevalence of ESBL producing organisms is increasing worldwide and several outbreaks have been reported. 13 In addition to increasing resistance to cephalosporins, resistance to other commonly used antibiotics such as fluoroquinolones is increasing. Clinical microbiology laboratories play a vital role in the detection and control of ESBL-producing Gram-negative bacilli. However, many laboratories are not fully aware of the importance of ESBL producing organisms and how best to detect them. In Europe it is estimated that 35% of ESBL producing organisms are incorrectly reported as susceptible to cephalosporins. ESBLs demonstrate low-level resistance in vitro. Routine disc susceptibility tests performed by laboratories may therefore fail to detect ESBL positive strains because these strains can be interpreted as sensitive to the extended spectrum cephalosporins. 1 The traditional susceptibility methods lack sensitivity and/or specificity and this issue has prompted the search for an accurate test to detect the presence of ESBLs. 14 Significant number of ESBL is also missed by Double disc synergy test; for this some authors recommended Three dimensional test for detection of ESBL producing strains. 7, 15 In this study a total of 110 Gram negative isolates were studied, of which 30 isolates from wound swab and 80 were laboratory isolates collected from different clinical samples. Among them 80% of the isolates were found ESBL producer. A study carried out in BSMMU by Rahman (2007) who found, ESBL in 30.90% strains of the Gm negative bacteria. It is important to note that percentage of ESBL producing bacteria has been increased from 30% to 80% in last 2 yrs among Gram negative bacteria in Bangladesh. The reason of this higher percentage of ESBL in present study may be due to indiscriminate use of 3rd generation cephalosporin. Extensive use of 3rd generation cephalosporin has contributed to the evolution of ESBL. 4 The reason of such high rates of ESBL production in all the strains in this study might be due to overall higher rate of ESBL producer in the study isolates. In the present study, TDT was found to be better that DDST in the detection of ESBL producing bacteria. Among the total 110 isolates ESBLs producer was found in 88 (80%) isolates by Three dimensional method and 73 (66.36%) by Double disc synergy method. So, 15 (13.63%) ESBL producing isolates were missed by Double disc synergy method. The difference in ESBL detection by Three dimensional test and Double disc synergy test was significant (p<0.05). The reason of such missing might be due to the coexistence of both ESBLs and plasmid-mediated Amp C β-lactamases when the Amp C β-lactamases is stably overproduced. Plasmid-mediated Amp C β-lactamases mask the synergistic effect of the clavulanic acid and the cephalosporin against ESBLs and may thus lead to false negative ESBL results. In order to detect ESBLs in the presence of Amp C β-lactamases, the use of fourth generation cephalosporins such as cefepime is required. 16 The low sensitivity of DDST may also be due to the inability of clavulanate to inhibit the ESBLs variant like IRT, CMT 17 , GES-2. 18 Moreover the penicillin-inhibitor combination, amoxicillin/clavulanic acid (AMC) is not active in vitro against a significant proportion of 14, 7 In the present study drug resistance of all ESBLs producer to most of the antibiotics (cephalosporin, aztreonam, cotrimoxazole, gentamycin, ciprofloxacin, amikacin) were found higher. This implies that ESBL producing organisms are multidrug resistant as genes that code for ESBL are linked to other resistant genes. 20 ESBL producing isolates were 100% sensitive to imipenem. According to CDC (1999), ESBLs are defined as enzymes which hydrolyze 3rd generation cephalosporins but sensitive to imipenem.
Screening for ESBL production needs to be carried out routinely in every clinical diagnostic laboratory to guide clinicians in proper selection of antibiotics. Continued monitoring of the susceptibility pattern of ESBL producing bacteria will provide invaluable information in proper clinical management.
